Figure 1. A) PRISMA flow diagram of study selection process
Figure 2. Risk of bias graph. A) Risk of bias summary B) Risk
for each included study.
Figure 3. Forest Plots of the effect of Roxadustat on
cardiovascular-related events. A) Forest Plots of the effect of
Roxadustat on cardiovascular-related events based on NDD or DD patients.
B) Forest Plots of the effect of Roxadustat on cardiovascular-related
events compared with placebo or ESA. All outcomes are reported in risk
ratios (RRs) for treatment vs the comparator and 95% credible intervals
(95%-CI).
Figure 4. Forest Plots of the effect of Roxadustat on renal
adverse events A) Forest Plots of the effect of Roxadustat on renal
adverse events based on NDD or DD patients. B) Forest Plots of the
effect of Roxadustat on renal adverse events compared with placebo or
ESA. All outcomes are reported in risk ratios (RRs) for treatment vs the
comparator and 95% credible intervals (95%-CI).
Figure 5. Forest Plots of the effect of Roxadustat on ESKD A)
Forest Plots of the effect of Roxadustat on ESKD based on NDD or DD
patients. B) Forest Plots of the effect of Roxadustat on ESKD compared
with placebo or ESA. All outcomes are reported in risk ratios (RRs) for
treatment vs the comparator and 95% credible intervals (95%-CI).
Figure 6. Forest Plots of the effect of Roxadustat on
hyperkalemia A) Forest Plots of the effect of Roxadustat on
hyperkalemia based on NDD or DD patients. B) Forest Plots of the effect
of Roxadustat on hyperkalemia compared with placebo or ESA. All outcomes
are reported in risk ratios (RRs) for treatment vs the comparator and
95% credible intervals (95%-CI).
Figure 7. Forest Plots of the effect of Roxadustat on
hypertension A) Forest Plots of the effect of Roxadustat on
hypertension based on NDD or DD patients. B) Forest Plots of the effect
of Roxadustat on hypertension compared with placebo or ESA. All outcomes
are reported in risk ratios (RRs) for treatment vs the comparator and
95% credible intervals (95%-CI).